MedPath

Concomitant psychotropic medication and electroconvulsive therapy on Schizophrenia

Phase 2
Conditions
schizophrenia.
Schizophrenia
Registration Number
IRCT201107143930N7
Lead Sponsor
Vice chancellor for research, Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Inclusive criteria: Diagnosed schizophrenia in accordance with DSM-IV, needs to be applied electroconvulsive therapy (ECT) determined by psychiatrist; providing written informed consent.

Exclusion Criteria

Patient who does not volunteer himself or herself, Serious neurological or medical damage such as epilepsy, diabetes, cardiac disease or autistic disorder.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The Positive and Negative Syndrome Scale for schizophrenia (PANSS). Timepoint: before first ECT session and about 4 weeks after the last session of ECT. Method of measurement: Interview.
Secondary Outcome Measures
NameTimeMethod
A modified version of Mini Mental Status Evaluation. Timepoint: before first ECT session, after every session of ECT, and about 4 weeks after the last session of ECT. Method of measurement: interview.
© Copyright 2025. All Rights Reserved by MedPath